Novel application of human neurons derived from induced pluripotent stem cells for highly sensitive botulinum neurotoxin detection

Toxicological Sciences

Volumn 126, Issue 2, 2012, Pages 426-435

  Whitemarsh, Regina C M ^a   Strathman, Monica J ^b   Chase, Lucas G ^a   Stankewicz, Casey ^b   Tepp, William H ^a   Johnson, Eric A ^a   Pellett, Sabine ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b Cellular Dynamics International Inc   (United States)

Author keywords

BoNT; Botulinum neurotoxin; Cell based assay; Induced pluripotent; Neurons; Stem cells

Indexed keywords

ANTIBODY; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXIN C; BOTULINUM TOXIN E; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CLOSTRIDIUM BOTULINUM; CONTROLLED STUDY; CRYOPRESERVATION; DOSE RESPONSE; EMBRYONIC STEM CELL; ENDOTOXIN DETECTION; HUMAN; INTOXICATION; MOUSE; NERVE CELL; NONHUMAN; PLURIPOTENT STEM CELL; QUANTITATIVE ANALYSIS; RAT; SENSITIVITY ANALYSIS; SPINAL CORD; WESTERN BLOTTING;

CLOSTRIDIUM BOTULINUM; RATTUS;

EID: 84859017992     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfr354     Document Type: Article

References (41)

1. Anson, B. D., Kolaja, K. L., and Kamp, T. J. (2011). Opportunities for use of human iPS cells in predictive toxicology. Clin. Pharmacol. Ther. 89, 754-758.
2. Arnon, S. S., Schechter, R., Inglesby, T. V., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Fine, A. D., Hauer, J., Layton, M., et al. (2001). Botulinum toxin as a biological weapon: Medical and public health management. JAMA 285, 1059-1070.
3. Bossi, P., Garin, D., Guihot, A., Gay, F., Crance, J. M., Debord, T., Autran, B., and Bricaire, F. (2006). Bioterrorism: Management of major biological agents. Cell Mol. Life Sci. 63, 2196-2212.
4. Cai, S., Singh, B. R., and Sharma, S. (2007). Botulism diagnostics: From clinical symptoms to in vitro assays. Crit. Rev. Microbiol. 33, 109-125.
5. Chaddock, J. A., and Acharya, K. R. (2011). Engineering toxins for 21st century therapies. FEBS J. 278, 899-904.
6. Dhaked, R. K., Singh, M. K., Singh, P., and Gupta, P. (2010). Botulinum toxin: Bioweapon & magic drug. Indian J. Med. Res. 132, 489-503.
7. Dong, M., Tepp, W. H., Johnson, E. A., and Chapman, E. R. (2004). Using fluorescent sensors to detect botulinum neurotoxin activity in vitro and in living cells. Proc. Natl. Acad. Sci. U.S.A. 101, 14701-14706.
8. Fischer, A., and Montal, M. (2007). Crucial role of the disulfide bridge between botulinum neurotoxin light and heavy chains in protease translocation across membranes. J. Biol. Chem. 282, 29604-29611.
9. Fischer, A., Nakai, Y., Eubanks, L. M., Clancy, C. M., Tepp, W. H., Pellett, S., Dickerson, T. J., Johnson, E. A., Janda, K. D., and Montal, M. (2009). Bimodal modulation of the botulinum neurotoxin protein-conducting channel. Proc. Natl. Acad. Sci. U.S.A. 106, 1330-1335.
10. Gimenez, D. F., and Gimenez, J. A. (1995). The typing of botulinal neurotoxins. Int. J. Food Microbiol. 27, 1-9.
11. Goodnough, M. C., Hammer, B., Sugiyama, H., and Johnson, E. A. (1993). Colony immunoblot assay of botulinal toxin. Appl. Environ. Microbiol. 59, 2339-2342.
12. Hall, Y. H., Chaddock, J. A., Moulsdale, H. J., Kirby, E. R., Alexander, F. C., Marks, J. D., and Foster, K. A. (2004). Novel application of an in vitro technique to the detection and quantification of botulinum neurotoxin antibodies. J. Immunol. Methods 288, 55-60.
13. Hatheway, C. L. (1988). Botulism. In Laboratory Diagnosis of Infectious Diseases: Principles and Practice (A. Balows, W. H. Hausler, M. Ohashi, and M. A. Turano, Eds.), pp. 111-133. Springer-Verlag, New York, NY.
14. Janz, R., and Sudhof, T. C. (1999). SV2C is a synaptic vesicle protein with an unusually restricted localization: Anatomy of a synaptic vesicle protein family. Neuroscience 94, 1279-1290.
15. Johnson, E. A. (2005). Clostridium botulinum and Clostridium tetani. In Topley and Wilson's Microbiology and Microbial Infections, 8th ed. (S. P. Borriello, P. R. Murray, and G. Funke, Eds.), pp. 1035-1088. Hodder Arnold, London.
16. Johnson, E. A., and Bradshaw, M. (2001). Clostridium botulinum and its neurotoxins: A metabolic and cellular perspective. Toxicon 39, 1703-1722.
17. Johnson, E. A., and Montecucco, C. (2008). Chapter 11 Botulism. In Handbook of Clinical Neurology (Andrew G. Engel, Ed.), pp. 333-368. Elsevier, Amsterdam, The Netherlands.
18. Keller, J. E., Cai, F., and Neale, E. A. (2004). Uptake of botulinum neurotoxin into cultured neurons. Biochemistry 43, 526-532.
19. Keller, J. E., Neale, E. A., Oyler, G., and Adler, M. (1999). Persistence of botulinum neurotoxin action in cultured spinal cord cells. FEBS Lett. 456, 137-142.
20. Kessler, K. R., Skutta, M., and Benecke, R. (1999). Long-term treatment of cervical dystonia with botulinum toxin A: Efficacy, safety, and antibody frequency. German Dystonia Study Group. J. Neurol. 246, 265-274.
21. Kiris, E., Nuss, J. E., Burnett, J. C., Kota, K. P., Koh, D. C., Wanner, L. M., Torres-Melendez, E., Gussio, R., Tessarollo, L., and Bavari, S. (2011). Embryonic stem cell-derived motoneurons provide a highly sensitive cell culture model for botulinum neurotoxin studies, with implications for highthroughput drug discovery. Stem Cell Res. 6, 195-205.
22. Lalli, G., Herreros, J., Osborne, S. L., Montecucco, C., Rossetto, O., and Schiavo, G. (1999). Functional characterisation of tetanus and botulinum neurotoxins binding domains. J. Cell. Sci. 112(Pt 16), 2715-2724.
23. Malizio, C. J., Goodnough, M. C., and Johnson, E. A. (2000). Purification of Clostridium botulinum type A neurotoxin. Methods Mol. Biol. 145, 27-39.
24. McNutt, P., Celver, J., Hamilton, T., and Mesngon, M. (2011). Embryonic stem cell-derived neurons are a novel, highly sensitive tissue culture platform for botulinum research. Biochem. Biophys. Res. Commun. 405, 85-90.
25. Montecucco, C., Rossetto, O., and Schiavo, G. (2004). Presynaptic receptor arrays for clostridial neurotoxins. Trends Microbiol. 12, 442-446.
26. Montecucco, C., and Schiavo, G. (1994). Mechanism of action of tetanus and botulinum neurotoxins. Mol. Microbiol. 13, 1-8.
27. National Institutes of Health. (2008). Report on the ICCVAM-NICEATM/ECVAM Scientific Workshop on Alternative Methods to Refine, Reduce or Replace the Mouse LD50 Assay for Botulinum Toxin Testing. NIH publication number 08-6416. Bethesda, MD.
28. Neale, E. A., Bowers, L. M., Jia, M., Bateman, K. E., and Williamson, L. C. (1999). Botulinum neurotoxin A blocks synaptic vesicle exocytosis but not endocytosis at the nerve terminal. J. Cell Biol. 147, 1249-1260.
29. Nuss, J. E., Ruthel, G., Tressler, L. E., Wanner, L. M., Torres-Melendez, E., Hale, M. L., and Bavari, S. (2010). Development of cell-based assays to measure botulinum neurotoxin serotype A activity using cleavage-sensitive antibodies. J. Biomol. Screen. 15, 42-51.
30. Oguma, K., Fujinaga, Y., Inoue, K., Yokota, K., Watanabe, T., Ohyama, T. K., and Inoue, K. (2000). Mechanisms of pathogenesis and toxin synthesis in Clostridium botulinum. Microbial Foodborne Diseases: Mechanisms of Pathogenesis and Toxin Synthesis (J. W. Cary, J. E. Linz, and D. Bhatnagar, Eds.), pp. 273-293. Technomic Pub. Co., Lancaster, PA.
31. Pellett, S., Du, Z. W., Pier, C. L., Tepp, W. H., Zhang, S. C., and Johnson, E. A. (2011). Sensitive and quantitative detection of botulinum neurotoxin in neurons derived from mouse embryonic stem cells. Biochem. Biophys. Res. Commun. 404, 388-392.
32. Pellett, S., Tepp, W. H., Clancy, C. M., Borodic, G. E., and Johnson, E. A. (2007). A neuronal cell-based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies. FEBS Lett. 581, 4803-4808.
33. Pellett, S., Tepp, W. H., Toth, S. I., and Johnson, E. A. (2010). Comparison of the primary rat spinal cord cell (RSC) assay and the mouse bioassay for botulinum neurotoxin type A potency determination. J. Pharmacol. Toxicol. Methods 61, 304-310.
34. Pier, C. L., Chen, C., Tepp, W. H., Lin, G., Janda, K. D., Barbieri, J. T., Pellett, S., and Johnson, E. A. (2011). Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1. FEBS Lett. 585, 199-206.
35. Prabakaran, S., Tepp, W., and DasGupta, B. R. (2001). Botulinum neurotoxin types B and E: Purification, limited proteolysis by endoproteinase Glu-C and pepsin, and comparison of their identified cleaved sites relative to the threedimensional structure of type A neurotoxin. Toxicon 39, 1515-1531.
36. Sakaguchi, G., Ohishi, I., and Koazki, S. (1988). Botulism-Structure and chemistry of botulinum. Bacterial Toxins: Handbook of Natural Toxins, (A.T. Tu, Ed.) Vol. 4, 191-216. Marcel Dekker Inc., New York, NY.
37. Schantz, E. J., and Kautter, D. A. (1978). Standardized assay for Clostridium botulinum toxins. J. Assoc. Off. Anal. Chem. 61, 96-99.
38. Sesardic, D., Jones, R. G., Leung, T., Alsop, T., and Tierney, R. (2004). Detection of antibodies against botulinum toxins. Mov. Disord. 19(Suppl. 8), S85-S91.
39. Stahl, A. M., Ruthel, G., Torres-Melendez, E., Kenny, T. A., Panchal, R. G., and Bavari, S. (2007). Primary cultures of embryonic chicken neurons for sensitive cell-based assay of botulinum neurotoxin: Implications for therapeutic discovery. J. Biomol. Screen. 12, 370-377.
40. Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., and Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861-872.
41. Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007). Induced pluripotent stem cell lines derived from human somatic cells. Science 318, 1917-1920.